Company intelligence / Profile preview

Mainstay Medical International

Dublin, Ireland

Ownership: Private
Employees: ~51
Development stage: Other

Overview

ReActiv8 has FDA Pre-Market Approval (PMA) in the US (2020), CE Mark in Europe (2016), TGA approval in Australia (2019), and is commercially available in US, Australia, Germany, UK, and other European markets. Clinical trials including ReActiv8-B (pivotal IDE, positive 3-5 year data), ReActiv8-C (post-market), and RESTORE (randomized superiority over standard care) demonstrate long-term efficacy in reducing pain and improving function in mechanical chronic low back pain associated with multifidus dysfunction.[1][2][3][8][14]

Therapeutic areas: Neurology
Modalities: DeviceRestorative Neurostimulation
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Mainstay Medical International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mainstay Medical International.

Explore the full profile